TITLE

Renal Nutrition Update

AUTHOR(S)
CONNERY, GRISSIM CLARK
PUB. DATE
May 2013
SOURCE
Renal & Urology News;May2013, Vol. 12 Issue 5, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the medical benefits offered by the Ghrelin hormone to the patients with chronic kidney disease (CKD). It states that the hormone reduces the muscle protein degradation and inflammatory cytokines. It cites that ghrelin infusion improves transcription factors linked with lipid metabolism. It also mentions that administering of acyl ghrelin increases serum ghrelin.
ACCESSION #
87627710

 

Related Articles

  • Increased Proinflammatory Cytokine Production and Decreased Cholesterol Efflux Due to Downregulation of ABCG1 in Macrophages Exposed to Indoxyl Sulfate. Koji Matsuo; Suguru Yamamoto; Takuya Wakamatsu; Yoshimitsu Takahashi; Kazuko Kawamura; Yoshikatsu Kaneko; Shin Goto; Kazama, Junichiro J.; Ichiei Narita // Toxins;Aug2015, Vol. 7 Issue 8, p3155 

    One of the possible causes of enhanced atherosclerosis in patients with chronic kidney disease (CKD) is the accumulation of uremic toxins. Since macrophage foam cell formation is a hallmark of atherosclerosis, we examined the direct effect of indoxyl sulfate (IS), a representative uremic toxin,...

  • The role of lipids and uremic toxins in cardiovascular disease in CKD. Massy, Ziad // Clinical & Experimental Nephrology;Apr2014, Vol. 18 Issue 2, p255 

    Lipid abnormalities and uremic toxins are features of chronic kidney disease (CKD) and may influence cardiovascular outcomes in CKD patients. Recent data suggest that uremic toxins may modulate lipoprotein levels and composition (e.g., oxidation or carbamylation) and enhance the cardiovascular...

  • Decrease in Irisin in Patients with Chronic Kidney Disease Wen, Ming-Shien; Wang, Chao-Yung; Lin, Shuei-Liong; Hung, Kuo-Chun // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Patients with chronic kidney disease have abnormal energy expenditure and metabolism. The mechanisms underlying altered energy expenditure in uremia are unknown and remain to be elucidated. Irisin is a peroxisome proliferator-activated receptor γ coactivator 1-α–dependent myokine,...

  • Lipoprotein metabolism and CKD: overview. Barter, Philip // Clinical & Experimental Nephrology;Apr2014, Vol. 18 Issue 2, p243 

    Patients with chronic kidney disease (CKD) frequently display abnormalities of plasma lipids and lipoproteins. These abnormalities include hypertriglyceridemia associated with elevated levels of very low-density lipoproteins (VLDLs) and chylomicrons. There is often also an increase in the...

  • Inflammation and cachexia in chronic kidney disease. Cheung, Wai; Paik, Kyung; Mak, Robert // Pediatric Nephrology;Apr2010, Vol. 25 Issue 4, p711 

    Chronic inflammation is associated with cachexia and increased mortality risk in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Inflammation suppresses appetite and causes the loss of protein stores. In CKD patients, increased serum levels of pro-inflammatory...

  • Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Breit, Samuel N.; Carrero, Juan J.; Tsai, Vicky Wang-Wei; Yagoutifam, Nasreen; Luo, Wei; Kuffner, Tamara; Bauskin, Asne R.; Wu, Liyun; Jiang, Lele; Barany, Peter; Heimburger, Olof; Murikami, Mary-Ann; Apple, Fred S.; Marquis, Christopher P.; Macia, Laurence; Lin, Shu; Sainsbury, Amanda; Herzog, Herbert; Law, Matthew; Stenvinkel, Peter // Nephrology Dialysis Transplantation;Jan2012, Vol. 27 Issue 1, p70 

    Background. Elevated macrophage inhibitory cytokine-1 (MIC-1/GDF15) levels in serum mediate anorexia and weight loss in some cancer patients and similarly elevated levels occur in chronic kidney disease (CKD). Serum MIC-1/GDF15 is also elevated in chronic inflammatory diseases and predicts...

  • The Impact of Chronic Kidney Disease and Short-Term Treatment with Rosiglitazone on Plasma Cell-Free DNA Levels. McGuire, Amanda L.; Urosevic, Nadia; Chan, Doris T.; Dogra, Gursharan; Inglis, Timothy J. J.; Chakera, Aron // PPAR Research;2014, p1 

    Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. Circulating free nucleic acids, known as cell-free DNA (cfDNA), have been proposed as a novel biomarker of cardiovascular risk. The impact of renal impairment on cfDNA levels and whether cfDNA is...

  • Inflammatory Cytokines in Diabetic Nephropathy. Donate-Correa, Javier; Martín-Núñez, Ernesto; Muros-de-Fuentes, Mercedes; Mora-Fernández, Carmen; Navarro-González, Juan F. // Journal of Diabetes Research;2/15/2015, Vol. 2015, p1 

    Probably, the most paradigmatic example of diabetic complication is diabetic nephropathy, which is the largest single cause of end-stage renal disease and a medical catastrophe of worldwide dimensions. Metabolic and hemodynamic alterations have been considered as the classical factors involved...

  • ANTI-OXIDANT ENZYME ACTIVITY IN POLYMORPHONUCLEAR LEUKOCYTES IN PATIENTS WITH VARYING SEVERITY OF CHRONIC KIDNEY DISEASE AND EFFECT OF FIRST ACUTE HEMODIALYSIS. Mahajan, Sandeep; Kalra, Om Prakash; Tripathi, Asit K. // Indian Journal of Nephrology;Jul-Sep2007, Vol. 17 Issue 3, p134 

    Introduction: Chronic kidney disease (CKD) is now being recognized as pro-oxidant state with increasing oxidative stress (OS) being implicated for increased incidence of cardiovascular disease (CAD) and progression of CKD. Hemodialysis (HD) by activation of cytokines and complement due to use of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics